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Background:  The  advent  of  new  HCV  drugs  has  generated  widespread  economic  concerns,  particularly
within  the  Italian  setting,  characterized  by continuous  linear  cuts  and  spending  review actions.  The  overall
trade-off  between  investments  and savings  needs  an  in depth  analysis.
Aims:  The  study  aimed  to  estimate  the budget  impact  of the  introduction  of  the  novel  drugs  approved
during  the  year  2015,  compared  with  the historical  situation  based  on the  different  treatment  options
available  prior  to  2015.
Methods:  A  three-year  budget  impact  model  was  developed,  taking  into  consideration  the  Lombardy
Region  (Northern  Italy)  Health  Service  perspective.  The  degree  of  liver  ﬁbrosis,  genotypes,  presence  of
only HCV  or  HIV/HCV  co-infections,  presence  or absence  of sustained  virological  response,  and  direct
healthcare  total  costs  were  the variables  of  the model.
Results:  With  the  introduction  of  the  novel  regimens,  a  higher  number  of HCV  patients  achieved  a
sustained  virological  response  (+20%).  Further  analysis  showed  that  an  investment  in innovative  tech-
nologies  would  have  given  the  Regional  System  signiﬁcant  economic  savings  within  the 36-month  period
(−6.64%/−7.15%).
Conclusions:  Treating  HCV-infected  persons  in  the Lombardy  Region  with  the  new  drugs  would  reduce
healthcare  expenditure  on  this  speciﬁc  disease,  in  each  forecast  implemented,  thus  reducing  the economic
burden  of  the pathology.
©  2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of Editrice  Gastroenterologica  Italiana  S.r.l.
ticle  uThis is an open  access  ar
. Introduction
Hepatitis C virus (HCV) infection represents a major global pub-
ic health problem, affecting approximately 160 million people
orldwide [1]. Literature estimated that, in Italy, 2 million peo-
le have the infection. However, the actual burden of HCV may  be
nderestimated due to the high number of undiagnosed infected
ubjects, often with latent disease, but at a signiﬁcant stage [2].Italian evidence now available [3,4], concerning the epidemiol-
gy and the prevalence of HCV, is inconsistent with reference to
he administration of anti-HCV medications, as reported in real life
∗ Corresponding author at: Corso Matteotti, 22, 21053 Castellanza (VA), Italy.
ax: +39 0331572513.
E-mail address: lferrario@liuc.it (L. Ferrario).
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590-8658/© 2016 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroen
http://creativecommons.org/licenses/by-nc-nd/4.0/).nder  the  CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
practice. Thus, an epidemiological gap emerged as a key issue to
be considered for the management of HCV infection, leading to
signiﬁcant difﬁculties in the forecast and evaluation of the eco-
nomic burden of disease for the Italian National Health Service
(NHS).
The coverage of the mentioned knowledge gap could be rele-
vant from a policy-making and pharmaco-economics point of view,
allowing an efﬁcient and effective economic resources allocation.
Italian spending review imposed, over the last three years, a deep
analysis of healthcare expenditures and required taking into partic-
ular consideration the assessment and introduction of healthcare
technologies. In this regard, attention should be focused on the
adoption of several new regimens made available in 2015 to clinical
practices, that may  represent important improvements if com-
pared with traditional interferon-based HCV treatments (before
May  2015).
terologica Italiana S.r.l. This is an open access article under the CC BY-NC-ND license
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The standard of care, up to 2011, was “dual therapy” that
sed Pegylated Interferon and Ribavirin. The approval, in 2011,
f the ﬁrst generation of direct-acting anti-virals (DAAs), such as
oceprevir and Telaprevir, increased the effectiveness of previous
reatments. However, in recent years (2014–2015), the landscape of
nti-HCV medications has rapidly evolved, with several more effec-
ive alternative technologies introduced in the market, worldwide.
hile these treatments increased the rate of sustained virologic
esponse (SVR), many patients were still unable to tolerate ther-
pies with Pegylated Interferon [5,6]. If the signiﬁcant increase
f eligible patients were considered, the economic and budgetary
mplications would generate widespread concerns.
In 2015, with the Italian approval of novel combinations of DAAs,
everal expensive Interferon-free treatment options were made
vailable: (i) Sofosbuvir/Ledipasvir; (ii) Daclatasvir + Sofosbuvir
nd (iii) Ombitasvir + Paritaprevir/Ritonavir + Dasabuvir, all
ssumed either alone or in association with Ribavirine.
An in-depth evaluation of the economic resources is there-
ore required for the proper and adequate treatment of HCV and
CV/HIV infected patients, in order to ﬁll a literature gap.
To the best of the authors’ knowledge, the present study
s the ﬁrst attempt to fully evaluate the budget impact of the
bove mentioned novel therapies, taking into consideration the
ombardy Region (Northern Italy) Health Service point of view,
hus paving the way to allow planning for regional resources as
roviders and patients face a new context for HCV treatment
ecision-making.
. Materials and methods
The study’s objective was achieved using a budget impact anal-
sis (BIA) approach, whose main purpose is to estimate and predict
conomic and ﬁnancial consequences referring to the adoption and
iffusion of new technologies into a healthcare system with ﬁnite
esources [7].
The model was developed from the Lombardy Region Health
ervice perspective and represented the healthcare expenditure
volution over three years.
Two different comparative scenarios were simulated: the
dministration of the three interferon-free drugs approved dur-
ng the year 2015 (innovative scenario) vs the historical situation
f pharmacological alternatives consumption, considering both
nterferon-free and Interferon-based strategies, representative of
ll treatments available prior to May  2015.
In accordance with this, (i) Sofosbuvir/Ledipasvir ± Ribavirine;
ii) Daclatasvir + Sofosbuvir ± Ribavirine and (iii) Ombitasvir +
aritaprevir/Ritonavir + Dasabuvir ± Ribavirine were included in
he innovative scenario. Otherwise, (iv) Simeprevir + Sofosbuvir ±
ibavirine, (v) Simeprevir + Pegylated Interferon + Ribavirine,
vi) Sofosbuvir + Ribavirine, (vii) Sofosbuvir + Pegylated Inter-
eron + Ribavirine, (viii) Pegylated Interferon + Ribavirine and
ix) PI old generation + Pegylated Interferon + Ribavirine, were part
f the baseline/historical scenario.
To build up the model, four phases were developed:
1. Input variables of the model.  All Lombardy Region subjects eli-
ible to the treatments, entering the BIA, were deﬁned and the
elated distribution was  estimated considering (a) Metavir Score,
etermining the severity of the disease, (b) genotypes, (c) only HCV
nfection or HCV/HIV co-infection, and (d) previous medical his-
ory (naïve and treatment experienced patients), on the basis of
iterature, regional [8] and real-life data collected from two Infec-
ious Disease Centres of Lombardy Region, involved in the analysis:
Ospedale di Circolo” of Busto Arsizio and “Luigi Sacco” of Milan
ospital Health Authorities (HHAs). Disease 48 (2016) 1200–1207 1201
Since no clear consensus exists with reference to the number
of HCV patients taken in charge in Lombardy Region, two  different
populations were hypothesized to be entered in the model, within
the ﬁrst year: (i) population related to the regional spending cap
[9], and (ii) population related to the organizational and produc-
tive cap (starting from the Regional Decree 7826, 2015). These two
assumptions were based on the declarations from the HHAs, taking
into consideration only patients suffering from more severe stages
of the disease (F3–F4), for whom the reimbursement indication was
available, and estimating the F0–F2 population, potentially eligible
to novel treatment, but assuming standard therapies.
The ﬁrst hypothesis considered 13,658 infected patients of
which 5395 were F3–F4 patients, for whom the Lombardy Region
budget limitation was widely veriﬁed. In the second hypothe-
sis, 31,722 HCV and HCV/HIV patients were considered, of which
12,530 subjects suffered from a severe stage of pathology (37,589
F3–F4 patients divided into three years of treatment due to capac-
ity limit), this being consistent with the capacity of the Lombardy
Region HHAs in terms of number of patients that could be treated
per year.
The HCV prevalence rate was 2.45% [10], applied to verify the
forecasts and hypotheses. The incidence of the disease was 0.016%
per year [11], useful to enter new patients in the second and
third year. Other relevant data used for the population progres-
sion, within the 24 and 36 months of analysis, were the number of
deceased patients due to HCV-related causes (0.23%) and others due
to hepatocellular carcinoma-HCC and decompensated cirrhosis-
DCC (1.45% [12,13]), focusing on the fact that HCV is known to have
an accelerated course in more than 30% of cases [6].
Furthermore, the model assumed that 30% of HIV infected
patients had a concomitant HCV infection, on the basis of litera-
ture evidence [14,15] and in accordance with declarations from the
HHAs involved.
The information regarding both the genotypes and the level of
liver disease was retrieved by the Regional Decree 7826, and the
related survey of November 2014. It was estimated that genotype
1 was  the most common (60%), followed by genotypes 2 and 3
(15%). Patients affected by genotype 4 were less than 8%. These data
were perfectly consistent with the most recent literature evidence
[10,16].
With regard to the degree of liver ﬁbrosis, the following rates
were assumed (starting from the Regional Decree 7826 and val-
idated with expert opinion): 28.50% (F0–F1), 32.00% (F2), 18.10%
(F3) and 21.40% (F4). F4 patients were distinguished as follows [17]:
62.4% (Child–Pugh class A), 23.8% (Child–Pugh class B) and 13.8%
(Child–Pugh class C).
The efﬁcacy data was  the sustained virological response, deﬁned
as the absence of detectable HCV RNA in the serum six months after
the completion of treatment [18,19]. This information, together
with the adverse events’ incidence rates, was retrieved from the
most recent clinical trials related to the different therapeutic regi-
mens under assessment, as presented in Table 1.
2. Budget impact model design.  The BIA design was  dependent on:
(i) the development of the population entering the model (point 1);
(ii) the economic evaluation related to the patients pathways (point
3); and (iii) the scenarios compared in the assessment (point 4)
(Fig. 1).
Patients could enter the model in one of the 138 possible health
states, deﬁned on the basis of: (i) genotype (1a, 1b, 2, 3, or 4), (ii)
degree of liver ﬁbrosis (F0, F1, F2, F3 or F4), (iii) previous clinical
history, (iv) presence or absence of SVR (SVR vs NO SVR) at the
end of the anti-HCV treatment, and related to the efﬁcacy data, (v)
presence of HCV infection or HCV/HIV co-infection. According to
this, four different populations were assumed.
F2 individuals could develop DCC, HCC, receive a liver trans-
plant, or die as a result of a liver-related cause: the higher the
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Table 1
Efﬁcacy rate sources of information, for HCV and HCV/HIV infected patients.
Treatment regimens Clinical trials
Ledipasvir/Sofosbuvir ± Ribavirine ION 1 [20], ION 2 [21], ION 4
[22], ELECTRON 2 [23], NIH
SINERGY [24]
Daclatasvir + Sofosbuvir ± Ribavirine A1444-040 [25], ALLY 2 [26],
ALLY 3 [27]
Simeprevir + Sofosbuvir ± Ribavirine COSMOS [28]
Ombitasvir + Paritaprevir/Ritonavir +
Dasabuvir ± Ribavirine
PEARL I [29], PEARL III [30],
PEARL VI [30], SAPPHIRE 1 [31],
SAPPHIRE 2 [32], TURQUOISE
[33]
Simeprevir + Pegylated
Interferon + Ribavirine
QUEST 1 [34], PROMISE [35],
RESTORE [36], C212 [37]
Sofosbuvir + Ribavirine NIH-SPARE [38], FISSION [39],
FUSION [40], Egyptian Ancestry
Trial [41], PHOTON II [42]
Sofosbuvir + Pegylated
Interferon + Ribavirine
NEUTRINO [39], NIH-SPARE
[38], ELECTRON [43],
LONESTAR 2 [44]
PI old SPRINT 2 [45], RESPOND 2 [46]
M
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ageneration + Pegylated
Interferon + Ribavirine
etavir Score, or the Child–Pugh, the higher the probability that
here will occur a disease progression and death. The evolution
f the population at different stages of pathology decreased the
umber of patients in the model: at the end of each year of anal-
sis, patients could either exit or enter the model (on the basis
f the death and HCV prevalence rate). Patients who  successfully
oved to SVR health state remained in the model for the whole
ime-period (after achieving SVR, their annual economic value was
omposed of their monitoring only). On the other hand, patients not
chieving SVR could remain in absence of cultural control, with a
Fig. 1. Budget impactr Disease 48 (2016) 1200–1207
higher risk of disease progression, or move to SVR population, in the
second or third cycle (with a lower economic resources absorption).
Both SVR and NO SVR patients could present the same incidence of
adverse events, aspect totally related to the treatment regimen.
3. Economic evaluation.  In order to conduct a complete BIA, the
economic evaluation of the above mentioned different categories
of patients (point 1), considering their whole clinical and diagnostic
HCV pathway, was  composed of the following aspects:
i) Annual costs of HCV treatment, considering (a) different stages
of disease, (b) presence or absence of co-infection, and (c)
achievement of SVR, on the basis of the HCV Lombardy Region
data [8] and standard clinical pathways carried out in the
two  HHAs involved (March–October 2015), with ﬁnal approval
from the clinicians of reference in accordance with the Del-
phi method [47]. The total amount of hematologic and cultural
exams, diagnostic and surgical procedures, outpatients and
medical examinations and hospital admissions were the inves-
tigated variables.
ii) Cost of drugs during treatment that varied between 8 and 48
weeks, in accordance with liver ﬁbrosis, HCV genotype, pres-
ence of HCV/HIV co-infection and pharmacological treatment
scheme.
iii) Cost of side effects management (in terms of laboratory exams,
diagnostic and surgical procedures, medical examinations and
hospital admissions), depending on the incidence and thera-
peutic strategy administered.The presented three items of expenditure considered a
time-horizon of 12, 24 and 36 months and were evaluated in accor-
dance with the 2015 Lombardy Region outpatients and hospital
admissions Reimbursement Tariffs. Drug costs derived from the
 model design.
E. Garagiola et al. / Digestive and Liver
Table  2
Cost of the diagnostic and follow-up monitoring.
F0–F1 F2 F3 F4
HCV patient
BASELINE D 414.12 D 414.12 D 414.12 D 414.12
SVR D 186.56 D 245.49 D 304.42 D 1648.40
NO  SVR D 373.12 D 484.30 D 595.48 D 7658.76
HCV/HIV patient
BASELINE D 414.12 D 414.12 D 414.12 D 414.12
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CSVR D 186.56 D 260.95 D 335.33 D 1888.34
NO  SVR D 373.12 D 499.76 D 626.39 D 7898.70
fﬁcially published NHS price list, and considering the Regional
ecree 7826.
4. Scenario and sensitivity analysis. In addition to the above
entioned population hypotheses, four different scenarios were
imulated: (i) 95,162 infected patients could enter the model [8];
ii) the whole Lombardy Region population (158,457 patients)
ould be eligible to HCV anti-viral treatment [8]; (iii) non-responder
atients included in the baseline scenario could receive innova-
ive therapies; and (iv) the novel regimens could be administered
o all the patients, independently from their level of liver ﬁbrosis
application of a 0% market share to Interferon-based therapies).
After the implementation of the BIA and the scenario analysis,
 sensitivity analysis was carried out by changing time-sensible
arameters (efﬁcacy rates and drugs’ prices). In order to account for
ower SVR rates in practice vs clinical trials as conducted by Chhat-
al and colleagues [48], a decrement of 2% and 5% was applied to
ach regimen. A decrease and an increase (±10%) in the drugs’ mar-
et prices were applied, both in the historical and in the innovative
cenario, in order to investigate if signiﬁcant changes in the BIA
ccurred.
. Results
.1. Economic evaluation of the HCV patient clinical pathway
The economic evaluation of the HCV patient clinical pathway
onsidered: (i) HCV diagnosis and follow-up, (ii) drugs cost, and
iii) the anti-viral monitoring and side-effect costs.
i) Table 2 shows the economic value related to the management of
a standard HCV and HCV/HIV patient, stratiﬁed by level of liver
ﬁbrosis: the more severe the pathology, the more signiﬁcant the
amount of economic resources absorbed for the management
of the patient.The baseline value referred to the introduction of the patient
into the taking in charge process, that requires hematologic and
cultural exams useful to investigate the absence or the pres-
ence of HCV infection. SVR and NO SVR costs are related to the
able 3
ost of the therapeutic regimens and the related monitoring.
Therapeutic regimen 
Ledipasvir/Sofosbuvir 
Ledipasvir/Sofosbuvir + Ribavirine 
Daclatasvir + Sofosbuvir 
Daclatasvir + Sofosbuvir + Ribavirine 
Simeprevir + Sofosbuvir 
Simeprevir + Sofosbuvir + Ribavirine 
Ombitasvir + Paritaprevir/Ritonavir + Dasabuvir 
Ombitasvir + Paritaprevir/Ritonavir + Dasabuvir + Ribavirine 
Simeprevir + Pegylated Interferon + Ribavirine 
Sofosbuvir + Ribavirine 
Sofosbuvir + Pegylated Interferon + Ribavirine 
Pegylated Interferon + Riba 
PI  old generation + Pegylated Interferon + Ribavirine  Disease 48 (2016) 1200–1207 1203
follow-up of a patient who  reaches, or does not reach, the viro-
logical control.
The difference between mono-infection and co-infection is
due to the fact that an HCV/HIV patient requires more frequent
controls both for HCV and HIV, since HIV is a leading cause of
HCV rapid evolution.
ii) The drugs’ costs presented in Table 3 are related to a single
week of treatment. The complete therapy’s administration was
calculated, distinguished by level of disease progression.
ii) Patients receiving the anti-HCV therapy should be monitored
during the administration of the treatment, undergoing spe-
ciﬁc procedures and exams regarding the investigation of the
strategy’s efﬁcacy and the possible development of drug-related
adverse events. The differences presented in Table 3 could be
explained by the different number of exams, in particular with
regard to the use of Ribavirine and Sofosbuvir that required
more frequent controls of blood count and creatinine.
In the real life setting, regional payers could take advantages
from price-volume discounts concerning Ledipasvir/Sofosbuvir,
Sofosbuvir, Ombitasvir + Paritaprevir/Ritonavir and Dasabuvir;
in the model, this discount rate was  applied on the basis of the
overall treated population entering the BIA cycles, and the use
of the previously mentioned drugs.
iv) The procedures concerning the management of drug-related
adverse event were evaluated, considering a 12-month period.
The most common adverse events were (i) fatigue (D 22.50), (ii)
bilirubin increase (D 84.75), (iii) insomnia (D 81.30), (iv) anemia
(D 5629.31), (v) pruritus (D 85.68), (vi) nausea (D 52.74), (vii)
rash (D 110.34) and (viii) neutropenia (D 1264.80).
3.2. Results from the budget impact analysis
The BIA was conducted with two different hypotheses’ popu-
lations, for whom the same trend could be found, considering the
decreasing of both the populations who  could not reach the viro-
logical control and the overall economic resources needed for the
entire management of the disease. With the introduction of the
novel regimens, more effective than those available prior to May
2015, the progression of the disease could be stopped in a higher
number of HCV and HCV/HIV patients.
Considering the ﬁrst hypothesis of real-data drugs consump-
tion, 13,658 patients entered the model in the ﬁrst year, and 14,195
individuals were treated at the end of 36 months. In comparison
with the baseline scenario, the innovative scenario reported an
increase in +20.16% of the patients’ virological control (equal to
1213 patients), over three years. The same trend was found in the
second hypothesis, in which 31,722 patients were included in the
model: a higher level of virological control was  registered and 2815
patients (+20.15%), who in the baseline scenario were classiﬁed as
“NO SVR” patients, became SVR.
Cost of the drug (included VAT 10%) Monitoring costs
D 3730.83 D 868.75
D 3745.68 D 876.85
D 4950.00 D 868.75
D 4964.85 D 876.85
D 4766.67 D 868.75
D 4781.52 D 876.85
D 2475.00 D 863.65
D 2489.85 D 871.75
D 1615.35 D 1082.95
D 3406.52 D 876.85
D 3632.02 D 1088.05
D 240.35 D 1082.95
D 1778.13 D 1082.95
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Table 4
Budget impact analysis and scenario analysis.
Treated HCV population Time-horizon NO SVR population HCV management costs Economic impact
Innovative
vs baseline
(N)
Innovative
vs baseline
(%)
Baseline Innovative Innovative vs
baseline
Innovative
vs baseline
(%)
Hypothesis 1
(N = 13,658)
12-Month period −688 −17.18 D 394,946,618.80 D 394,050,223.35 −D 896,395.45 −0.23
24-Month period −402 −26.87 D 127,327,739.83 D 98,374,098.80 −D 28,953,641.03 −22.74
36-Month period −123 −23.88 D 43,444,752.10 D 35,723,183.43 −D 7,721,568.67 −17.77
Total −1213 D 565,719,110.73 D 528,147,505.58 −D 37,571,605.15
Hypothesis 2
(N = 31,722)
12-Month period −1597 −17.17 D 683,684,838.71 D 695,397,772.61 D 11,712,933.90 1.71
24-Month period −932 −26.82 D 242,910,054.69 D 177,189,910.41 −D 65,720,144.28 −27.06
36-Month period −286 −23.91 D 91,941,391.53 D 73,166,191.10 −D 18,775,200.43 −20.42
Total −2815 D 1,018,536,284.94 D 945,753,874.12 −D 72,782,410.81
Scenario analysis – increase of the population eligible to treatment
Scenario 1
(N = 95,162)
12-Month period −4791 −17.17 D 2,050,968,255.43 D 1,875,351,587.36 −D 175,616,668.08 −8.56
24-Month period −2794 −26.81 D 728,684,141.94 D 490,843,086.37 −D 237,841,055.57 −32.64
36-Month period −858 −23.93 D 275,725,784.74 D 202,482,454.21 −D 73,243,330.53 −26.56
Total −8443 D 3,055,378,182.12 D 2,568,677,127.94 −D 486,701,054.17
Scenario 2
(N = 158,457)
12-Month period −7979 −17.17 D 3,415,126,935.99 D 3,122,715,984.99 −D 292,410,951.00 −8.56
24-Month period −4653 −26.82 D 1,213,362,793.92 D 817,280,737.62 −D 396,082,056.30 −32.64
36-Month period −1426 −23.89 D 459,045,184.70 D 337,120,468.61 −D 121,924,716.09 −26.56
Total −14,058 D 5,087,534,914.62 D 4,277,117,191.22 −D 810,417,723.40
Scenario 3
(N = 13,658)
12-Month period −688 −17.18 D 394,946,618.80 D 394,050,223.35 −D 896,395.45 −0.23
24-Month period −217 −16.55 D 119,395,163.86 D 98,374,098.80 −D 21,021,065.06 −17.61
36-Month period −75 −16.06 D 41,810,513.79 D 35,723,183.43 −D 6,087,330.35 −14.56
Total −980 D 556,152,296,44 D 528,147,505.58 −D 28,004,790.86
Scenario 4
(N = 31,722)
12-Month period −1597 −17.17 D 683,684,838.71 D 695,397,772.61 D 11,712,933.90 1.71
24-Month period −502 −16.49 D 211,413,480.40 D 177,189,910.41 −D 34,223,569.98 −16.19
36-Month period −173 −15.97 D 85,889,566.67 D 73,166,191.10 −D 12,723,375.57 −14.81
Total −2272 D 980,987,885.77 D 945,753,874.12 −D 35,234,011.65
Scenario 5
(N = 13,658)
12-Month period −2444 −61.02 D 294,362,509.80 D 280,680,315.20 −D 13,682,194.61 −4.65
24-Month period −992 −66.31 D 104,578,125.93 D 38,958,887.73 −D 65,619,238.21 −62.75
36-Month period −344 −66.80 D 39,581,306.29 D 17,518,860.79 −D 22,062,445.50 −55.74
Total −3780 D 438,521,942.03 D 337,158,063.72 −D 101,363,878.31
Scenario 6
(N = 31,722)
12-Month period −5678 −61.04 D 683,684,838.71 D 651,906,633.99 −D 31,778,204.72 −4.65
24-Month period −2305 −66.33 D 242,910,054.69 D 90,456,898.38 −D 152,453,156.31 −62.76
D
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T36-Month period −799 −66.81 
Total −8782 
The introduction of the innovative technologies would, there-
ore, give the Health Service a signiﬁcant economic saving, equal to
6.64% or −7.15% depending on the number of treated patients. The
nitial investment in innovative therapies could be covered in 24
onths, generating relevant beneﬁts for the Regional Service that
ould be consolidated in time. With the inclusion in the model of the
1,722 HCV and HCV/HIV patients, Lombardy Region would achieve
n economic advantage, considering an overall baseline cost equal
o D 1,018,536,284.93 and an innovative scenario resources absorp-
ion of D 945,753,874.12, over three years. Although the increase of
he population to be treated would raise the HCV health budget
t an investment equal to twice the resources made available by
he Italian Ministry of Health, the situation would generate eco-
omic savings exactly twice as much with respect to the previous
orecast.
While hypothesis 1 shows in the ﬁrst year an immediate eco-
omic saving, hypothesis 2 shows an incremental, but moderate
esources absorption of 1.71%; however, this is amply rewarded in
he second cycle of the model. The two apparently different results
n a short time-horizon clearly suggest the importance of moni-
oring the number of patients enrolled and treated, in order to
aximize and optimize the discount policies, thus achieving the
reatest beneﬁt for the NHS.
Furthermore, six scenario analyses were performed, concern-
ng the increase of HCV patients potentially eligible to treatment.
he ﬁrst scenario, based on the survey mentioned in the Decree 91,941,391.53 D 40,684,093.14 −D 51,257,298.39 −55.75
018,536,284.94 D 783,047,625.51 −D 235,488,659.42
7826, recorded 37,589 patients with positive HCV-RNA, treated by
the Lombardy Region HHAs. Moving on from this data (consider-
ing only F3 and F4 patients), the overall number of HCV infected
patients was estimated to be 95,162. The second scenario anal-
ysis considered all the Lombardy Region HCV infected patients,
on the basis of the HCV prevalence rate, resulting in a starting
population entering the model of 158,457 patients. Hence, the
introduction of the novel therapeutic regimens showed a signif-
icant increase of HCV patients who  achieved the SVR (+20.15%),
and a substantial economic saving of −15.93% in both cases
(Table 4).
The results highlighted in the BIA did not vary signiﬁcantly even
if, in the baseline scenario, non-responder patients were treated
with the innovative regimens in the second and in the third cycle
(scenarios 3 and 4). The innovative scenario always represents the
preferable “standard of care”, decreasing the number of NO SVR
patients by −16.95% and providing the regional health Service with
an economic advantage reducing the amount of resources required
for the treatment of all the eligible patients, considering a range
variable from −3.59% (N = 31,722) to −5.04% (N = 13,658).
Moreover, if the innovative drugs were available for the treat-
ment of all the patients (including F0–F2 individuals), with the
consequent avoidance of Interferon-based combinations (scenar-
ios 5 and 6), the related beneﬁts would be signiﬁcantly higher and
would not present a difference in the case of 13,658 or 31,722
individuals treated. Over the three-year period, there emerged an
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Table  5
Sensitivity analysis.
Treated HCV
population
Time-horizon NO SVR population HCV management costs Economic impact
Innovative
vs baseline
(N)
Innovative
vs baseline
(%)
Baseline Innovative Innovative vs
baseline
Innovative
vs baseline
(%)
1. Efﬁcacy rate
−2% (N = 13,658)
12-Month period −688 −16.08 D 395,347,750.90 D 394,451,355.45 −D 896,395.45 −0.23
24-Month period −426 −25.30 D 134,794,726.63 D 105,857,764.38 −D 28,936,962.25 −21.47
36-Month period −136 −22.33 D 48,178,065.94 D 39,854,714.48 −D 8,323,351.46 −17.28
Total  −1250 D 578,320,543.47 D 540,163,834.31 −D 38,156,709.16
2.  Efﬁcacy rate
−2% (N = 31,722)
12-Month period −1597 −16.07 D 684,616,506.05 D 696,329,439.95 D 11,712,933.90 1.71
24-Month period −991 −25.33 D 257,194,387.68 D 190,653,598.66 −D 66,540,789.02 −25.87
36-Month period −318 −22.47 D 102,003,331.77 D 81,525,220.21 −D 20,478,111.56 −20.08
Total  −2906 D 1,043,814,225.50 D 968,508,258.82 −D 75,305,966.68
3.  Efﬁcacy rate
−5% (N = 13,658)
12-Month period −687 −14.65 D 395,949,449.05 D 395,053,053.60 −D 896,395.45 −0.23
24-Month period −465 −23.40 D 146,040,112.52 D 117,155,339.52 −D 28,884,773.00 −19.78
36-Month period −161 −20.83 D 55,900,531.56 D 46,517,017.18 −D 9,383,514.38 −16.79
Total  −1313 D 597,890,093.12 D 558,725,410.30 −D 39,164,682.83
4.  Efﬁcacy rate
−5% (N = 31,722)
12-Month period −1597 −14.67 D 686,014,007.05 D 697,726,940.95 D 11,712,933.90 1.71
24-Month period −1078 −23.36 D 278,715,466.18 D 210,940,641.98 −D 67,774,824.20 −24.32
36-Month period −373 −20.77 D 118,289,506.26 D 95,180,721.09 −D 23,108,785.17 −19.54
Total  −3048 D 1,083,018,979.49 D 1,003,848,304.02 −D 79,170,675.47
5.  Drugs’ price
−10% (N = 13,658)
12-Month period −688 −17.18 D 363,916,583.14 D 362,486,336.67 −D 1,430,246.47 −0.39
24-Month period −402 −26.87 D 117,358,728.84 D 90,586,980.30 −D 26,771,748.54 −22.81
36-Month period −123 −23.88 D 40,137,071.50 D 32,992,805.21 −D 7,144,266.28 −17.80
Total  −1213 D 521,412,383.48 D 486,066,122.19 −D 35,346,261.29
6.  Drugs’ price
−10% (N = 31,722)
12-Month period −1597 −17.17 D 634,976,644.31 D 644,070,107.30 D 9,093,462.98 1.43
24-Month period −932 −26.82 D 225,038,744.70 D 164,233,671.17 −D 60,805,073.53 −27.02
36-Month period −286 −23.91 D 85,155,586.94 D 67,806,526.35 −D 17,349,060.59 −20.37
Total  −2815 D 945,170,975.95 D 876,110,304.81 −D 69,060,671.14
7.  Drugs’ price
+10% (N = 13,658)
12-Month period −688 −14.79 D 426,926,835.37 D 426,564,500.51 −D 362,334.85 −0.08
24-Month period −464 −23.63 D 156,420,094.59 D 125,288,583.40 −D 31,131,511.19 −19.90
36-Month period −161 −21.13 D 59,474,785.48 D 49,431,161.44 −D 10,043,624.04 −16.89
Total  −1313 D 642,821,715.43 D 601,284,245.35 −D 41,537,470,08
8.  Drugs’ price
+10% (N = 31,722)
12-Month period −1597 −17.17 D 718,807,671.25 D 733,942,331.86 D 15,134,660.60 2.11
24-Month period −932 −26.82 D 256,383,996.97 D 186,022,355.64 −D 70,361,641.33 −27.44
36-Month period −286 −23.91 D 97,180,223.83 D 76,954,135.19 −D 20,226,088.64 −20.81
D 1,
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mportant reduction of patients who did not achieve a sustained
irological control (−62.84%), with an economic saving of −23.12%.
.3. Sensitivity analysis
All results deriving from the sensitivity analysis show the
obustness of the proposed BIA. Even with a decrease in all the treat-
ents’ efﬁcacy rates (from −2% to −5%) Lombardy Region would
chieve an economic saving of −6.60% and a consequent increase
f responder patients (+18%), in the treatment of 13,658 or 31,722
nfected individuals.
If the price of the drugs (excluding VAT −10%) were included
n the model, the innovative regimens would result in an economic
dvantage variable from −6.78% (N = 13,658) to −7.31% (N = 31,722)
ver three years. By applying an increase of +10% to all the ther-
peutic strategies, the novel drugs would give cost reductions of
6.46% and −7.04%, with reference to the two different investigated
opulations respectively (Table 5).
. Discussion
This model provides clinicians and policy makers with a rational
ethod to allocate HCV patients to the correct alternatives, with aonsistent economic forecast, in a general context of limited eco-
omic resources and dynamic changing options for HCV treatment.
The results showed that treating eligible HCV-infected F3–F4
ersons in Lombardy Region with the new drugs would decrease072,371,892.05 D 996,918,822.68 −D 75,453,069.37
the related healthcare expenditure, thus reducing the eco-
nomic burden of the pathology, disinvesting resources for the
implementation of new technologies and/or guaranteeing the best
treatment for a greater number of patients.
Therefore, the population potentially eligible for treatment has
emerged as the main factor leading to a signiﬁcant change in the
overall HCV healthcare expenditure: the higher number of patients
treated, the higher the possibility to take advantage from the inno-
vative therapies’ discount rate.
Indeed, the treatment of all the F0–F4 patients with the novel
regimens would generate greater savings for the NHS, if compared
with the historical situation. If the economic resources (ﬁrst year)
needed for the treatment of 13,658 patients (hypothesis 1) are com-
pared with the overall HCV expenditure required for the treatment
of the regional eligible population (scenarios 1 and 2), it emerges
that the time for the return on investment is around three years.
Such a result is impressive, but partial: the investment required for
adapting the hospitals organizational capacity should be consid-
ered for a complete evaluation.
In addition, the model could be easily adapted with the inclu-
sion of the entire Italian HCV population suffering from the disease.
In particular, literature evidence [49] declared that, in the national
setting, the estimated number of F3–F4 patients is about 187,756
(referring to the entire year 2015). Moving on from this informa-
tion, the overall number of HCV infected Italian patients potentially
eligible to treatment is equal to 475,332: in particular, 135,470
were F0–F1, 152,106 were F2, 86,035 were F3 and 101,721 were
1 d Live
F
t
s
e
p
e
r
S
p
i
a
a
t
r
r
e
a
d
i
o
s
t
h
n
c
C
N
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[206 E. Garagiola et al. / Digestive an
4. Considering the drugs’ reimbursement indications (year 2015),
he treatment of Italian HCV patients would lead the NHS to a
igniﬁcant economic saving (−15.93%), thus also increasing the
ffectiveness of the treatment strategies (−20.14% of NO SVR
atients) within 36 months. This consideration is further strength-
ned if all the individuals (F0–F4) were treated with the innovative
egimens, avoiding interferon-free therapies: given an increase of
VR patients (+10.57%), HCV Italian healthcare expenditure would
resent a reduction of −37.48%.
Despite the relevance of the results, the model has several lim-
tations.
First, the SVR rates were retrieved from the clinical trials avail-
ble for each strategy, targeting different patient cohorts, as the
nalysis was not based on an observational study. Second, within
he national setting, there has been a lack of recent information
elated to both the prevalence/incidence of HCV infection, and the
eal patients distribution concerning the genotypes and the lev-
ls of liver ﬁbrosis, that could contribute to a better control and
ppropriate care of infected individuals.
In conclusion, the model did not consider long-term beneﬁts
erived from the novel drugs’ administration, leading to a reduction
n the number of HCV-related deaths and of HCC or liver transplant
ccurrence [50].
Therefore, it could be an interesting topic for future research to
tudy the update of the results, with the inclusion and the inves-
igation of other different costs, impacting on the overall HCV
ealthcare expenditure as well as taking into consideration the
umber of Italian HCV patients treated in 2016 (representing pre-
isely the ﬁrst year, after the new DAAs approval).
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